People living with HIV on antiretroviral therapy face elevated cardiovascular risk. A small study of 177 men on HAART found a variant in RYR3 — a gene that regulates calcium release in vessel-wall muscle — associated with an early ultrasound marker of artery narrowing, reported honestly as a first finding rather than a settled one.
People living with HIV on antiretroviral therapy (ART) face a higher rate of cardiovascular disease than the general population, for reasons that include the virus's own chronic inflammatory effects, some ART regimens' metabolic side effects, and the same traditional cardiovascular risk factors — blood pressure, cholesterol, smoking — that apply to everyone. Carotid intima-media thickness (IMT) is a small, non-invasive ultrasound measurement of the carotid artery wall, used as an early, subclinical marker of atherosclerosis before it becomes symptomatic disease.
Shrestha et al. 2010 ran a genome-wide association study in 177 HIV-positive men of European ancestry receiving HAART (highly active antiretroviral therapy), looking specifically for genetic contributors to carotid IMT in this population — not in HIV-negative people, and not looking at cardiovascular disease broadly. They found two SNPs in RYR3 (ryanodine receptor 3), including the variant on this page, associated with increased common carotid IMT.
RYR3 is a biologically plausible candidate rather than an arbitrary statistical hit: ryanodine receptors regulate calcium release in muscle cells, including the smooth muscle in blood vessel walls — directly relevant machinery for vascular biology, not a gene with no obvious connection to the trait.
This is a small study by the standards of most genetics research, and the honest thing to say about it is plain: 177 people is enough to report a finding worth further investigation, not enough to be a settled result.
2026-06-25 · Genome-wide association study of cardiovascular disease in people with HIV from the Million Veteran Program (MVP). AIDS. 2026. DOI:10.1097/qad.0000000000004504
People with HIV (PWH) have roughly twice the cardiovascular disease (CVD) risk of the general population even with effective antiretroviral therapy, but this excess risk's genetic basis in PWH specifically had not been studied. This multiancestry GWAS of 7,951 PWH from the Million Veteran Program identified a novel locus on chromosome 2 near NAT8 associated with CVD. NAT8 is linked to renal function and oxidative stress, both biologically plausible contributors to CVD in this population -- HIV itself and long-term antiretroviral use both affect kidney function and oxidative stress pathways. This is a small but genuinely novel study: the first to search specifically within a PWH cohort for CVD genetic risk factors that might differ from the general population, rather than assuming general-population CVD genetics applies unchanged. This site's carotid atherosclerosis in HIV infection page carries just 1 variant; NAT8 is a real addition to a page this thin.
Standard cardiovascular risk management — blood pressure, cholesterol, smoking cessation — applies fully to people living with HIV, alongside effective, consistent antiretroviral therapy. This variant, from a 177-person study, does not change any of that. Carotid IMT screening and cardiovascular risk assessment in this population are decisions for an HIV specialist and cardiologist working together, not something this page informs.
A study this size in one specific population (HIV-positive men on HAART, European ancestry) is a genuine first step. Whether this finding replicates in larger or more diverse cohorts is an open question this page does not resolve.
Blood pressure and cholesterol variants elsewhere on this catalogue apply to cardiovascular risk generally; this page is about a finding specific to the HIV-and-ART context.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Carotid Atherosclerosis in HIV Infection comes down to these specific, well-studied positions — not a diagnosis.
Databases, guidelines and references
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Carotid Atherosclerosis in HIV Infection. MyGeneLog™. https://www.mygenelog.com/conditions/carotid-atherosclerosis-in-hiv-infection
No. It comes from a 177-person study of one subclinical ultrasound marker, not a diagnosis or a validated risk predictor. Standard cardiovascular risk factors and consistent antiretroviral therapy remain the established, actionable considerations.
People on antiretroviral therapy face elevated cardiovascular risk from a mix of the virus's inflammatory effects, some treatment regimens' metabolic effects, and standard risk factors — a genetic contributor specific to this context would not necessarily show up in a study of the general population.
It is a ryanodine receptor, regulating calcium release in muscle cells including the smooth muscle of blood vessel walls — a mechanistically plausible connection to artery-wall thickening, though this study establishes a statistical association rather than proving the mechanism.
It is small by the standards of most genetics research on this site, and this page says so rather than treating the finding as settled. It is a legitimate first finding worth further study, not a result strong enough to act on individually.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog™. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.